# Kythera Biopharmaceuticals clinical trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Kythera Biopharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kythera Biopharmaceuticals: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/kythera-biopharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 8, 2015 | NCT02438813 | Condition of Submental Fullness and Treatment Outcomes Registry | Kythera Biopharmaceuticals | Observational | Completed | Submental Fullness | 1,029 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02438813) |
| June 16, 2014 | NCT02163902 | Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 | Kythera Biopharmaceuticals | Phase 3 | Completed | Submental Fat, Healthy | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02163902) |
| June 10, 2014 | NCT02159729 | Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 | Kythera Biopharmaceuticals | Phase 2 | Completed | Submental Fat, Healthy | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02159729) |
| April 25, 2014 | NCT02123134 | Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate to Severe Convexity of Submental Fat, Safety, Efficacy | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02123134) |
| January 14, 2014 | NCT02035267 | Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate to Severe Convexity of Submental Fat, Safety, Efficacy | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02035267) |
| December 10, 2013 | NCT02007434 | Patient Experience Study of Deoxycholic Acid Injection | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02007434) |
| October 15, 2012 | NCT01706679 | Evaluation of the Effect of ATX-101 on QT/QTc Intervals | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01706679) |
| July 3, 2012 | NCT01632917 | Open-Label Pharmacokinetic Study of Final Formulations of ATX-101 | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01632917) |
| March 7, 2012 | NCT01546142 | Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 516 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01546142) |
| March 1, 2012 | NCT01542034 | Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 506 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01542034) |
| October 31, 2011 | NCT01462786 | To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101 | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01462786) |
| August 31, 2011 | NCT01426373 | Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01426373) |
| March 22, 2011 | NCT01320761 | A Study to Assess Injection Comfort of Two Formulations of ATX-101 | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01320761) |
| March 22, 2011 | NCT01319916 | Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01319916) |
| February 28, 2011 | NCT01305577 | Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01305577) |
| February 11, 2011 | NCT01294644 | Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat | Kythera Biopharmaceuticals | Phase 3 | Completed | Moderate or Severe Submental Fullness | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01294644) |
| December 16, 2009 | NCT01032889 | Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study | Kythera Biopharmaceuticals | Phase 2 | Completed | Moderate or Severe Submental Fullness | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01032889) |
| February 4, 2009 | NCT00835952 | ATX-101 Abdominoplasty | Kythera Biopharmaceuticals | Phase 1 | Completed | Characteristics of Subcutaneous Fat | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00835952) |
| February 20, 2008 | NCT00618722 | Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | Kythera Biopharmaceuticals | Phase 1/2 | Completed | Moderate or Severe Submental Fullness | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00618722) |
| February 20, 2008 | NCT00618709 | Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 | Kythera Biopharmaceuticals | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00618709) |
| February 20, 2008 | NCT00618618 | Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat | Kythera Biopharmaceuticals | Phase 2 | Completed | Moderate or Severe Submental Fullness | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00618618) |
| February 6, 2008 | NCT00608842 | Phase 2 Study for the Treatment of Superficial Lipomas | Kythera Biopharmaceuticals | Phase 2 | Completed | Lipoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00608842) |
| January 15, 2007 | NCT00422188 | Deoxycholic Acid Injection for the Treatment of Superficial Lipomas | Kythera Biopharmaceuticals | Phase 1 | Completed | Lipoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00422188) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 9 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, Follicular | 9 |
| Lipoma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wallpaper installers in the United States](https://specstream.ai/data/businesses/wallpaper-installers/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Civil rights law firms in the United States](https://specstream.ai/data/businesses/civil-rights-law-firms/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [B2B oil and gas equipment companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-equipment-companies/united-states)
